iF647 Anti-Human CD33 Antibody
英诺赛图(InnoCyto)的 iF647 Anti-Human CD33 Antibody(克隆 Lintuzumab) 为人源 IgG1 单克隆抗体,靶向 CD33(别名 Siglec-3 等),iF647 标记(633 nm 红色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥1,627 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 iF647 Anti-Human CD33 Antibody(克隆 Lintuzumab) 为人源 IgG1 单克隆抗体,靶向 CD33(别名 Siglec-3 等),iF647 标记(633 nm 红色激光激发),适用于流式细胞术。提供 25 tests、100 tests 规格,目录价 ¥1,627 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
114907 | 25 tests | ¥1,763
114908 | 100 tests | ¥3,661
116701 | 25 tests | ¥1,627
116702 | 100 tests | ¥3,390
116801 | 25 tests | ¥1,763
116802 | 100 tests | ¥4,000
Product Details
Regulatory Status|RUO
Protein Concentration|Supplied at a lot-specific concentration.
Storage&Handling|The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended Usage|For flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. iF647 has an excitation max at 656 nm and an emission max at 670 nm.
Price (Converted)|1763
See All Formats|Clone Lintuzumab
Background Information
Human CD33 is a sialic acid–binding immunoglobulin-like lectin (Siglec-3) expressed primarily on myeloid lineage cells, including monocytes, myeloid progenitors, and some dendritic cells. It functions as an inhibitory receptor that modulates immune cell activation through intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Structurally, CD33 is a type I transmembrane glycoprotein composed of an extracellular domain with Ig-like folds that bind sialylated glycans, a single transmembrane region, and a cytoplasmic tail containing signaling motifs. Its ligands are sialic acid–containing glycoproteins and glycolipids commonly found on cell surfaces, enabling it to regulate cell–cell interactions and dampen immune responses.
CD33 is highly relevant in disease, particularly in acute myeloid leukemia (AML), where it is overexpressed on leukemic blasts, making it a valuable diagnostic marker and therapeutic target. Lintuzumab is a humanized monoclonal antibody directed against CD33 that binds the extracellular domain and promotes immune-mediated cytotoxicity, including antibody-dependent cellular cytotoxicity (ADCC). Although unconjugated lintuzumab has shown modest efficacy, it has been explored in combination therapies and as a targeting moiety for antibody-drug conjugates or radioimmunotherapy. Targeting CD33 allows selective elimination of malignant myeloid cells while sparing non-myeloid tissues, positioning CD33-directed agents, including lintuzumab-based strategies, as important components in AML therapeutic development.
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). iF647 Anti-Human CD33 Antibody(116801)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/if647-anti-human-cd33-antibody-116801.html.
TeleVM. (2026, November 12). iF647 Anti-Human CD33 Antibody(116801). 产品目录. https://www.suprotek.cn/products/item/if647-anti-human-cd33-antibody-116801.html
@misc{biocsp_item_if647_anti_human_cd33_antibody_116801,
title = {iF647 Anti-Human CD33 Antibody(116801)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/if647-anti-human-cd33-antibody-116801.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源